1. Home
  2. CRSP vs REYN Comparison

CRSP vs REYN Comparison

Compare CRSP & REYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • REYN
  • Stock Information
  • Founded
  • CRSP 2013
  • REYN 1947
  • Country
  • CRSP Switzerland
  • REYN United States
  • Employees
  • CRSP N/A
  • REYN N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • REYN Office Equipment/Supplies/Services
  • Sector
  • CRSP Health Care
  • REYN Industrials
  • Exchange
  • CRSP Nasdaq
  • REYN Nasdaq
  • Market Cap
  • CRSP 5.6B
  • REYN 5.0B
  • IPO Year
  • CRSP 2016
  • REYN 2020
  • Fundamental
  • Price
  • CRSP $52.57
  • REYN $24.23
  • Analyst Decision
  • CRSP Buy
  • REYN Hold
  • Analyst Count
  • CRSP 19
  • REYN 8
  • Target Price
  • CRSP $71.94
  • REYN $26.75
  • AVG Volume (30 Days)
  • CRSP 2.5M
  • REYN 1.1M
  • Earning Date
  • CRSP 11-10-2025
  • REYN 10-29-2025
  • Dividend Yield
  • CRSP N/A
  • REYN 3.80%
  • EPS Growth
  • CRSP N/A
  • REYN N/A
  • EPS
  • CRSP N/A
  • REYN 1.44
  • Revenue
  • CRSP $38,337,000.00
  • REYN $3,707,000,000.00
  • Revenue This Year
  • CRSP N/A
  • REYN $1.76
  • Revenue Next Year
  • CRSP $391.94
  • REYN $1.97
  • P/E Ratio
  • CRSP N/A
  • REYN $16.83
  • Revenue Growth
  • CRSP N/A
  • REYN 0.71
  • 52 Week Low
  • CRSP $30.04
  • REYN $20.91
  • 52 Week High
  • CRSP $78.48
  • REYN $28.66
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 34.88
  • REYN 49.02
  • Support Level
  • CRSP $52.42
  • REYN $24.56
  • Resistance Level
  • CRSP $58.48
  • REYN $25.00
  • Average True Range (ATR)
  • CRSP 3.56
  • REYN 0.67
  • MACD
  • CRSP -1.14
  • REYN -0.03
  • Stochastic Oscillator
  • CRSP 21.64
  • REYN 32.18

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About REYN Reynolds Consumer Products Inc.

Reynolds Consumer Products Inc is a provider of household products. The firm is engaged in the production and sales of cooking products, waste and storage products, and tableware. It operates through four reportable segments namely, Reynolds Cooking and Baking, Hefty Waste and Storage, Hefty Tableware, and Presto Products. Reynolds Cooking and Baking segment produce branded and store brand aluminum foil, disposable aluminum pans, parchment paper, freezer paper, wax paper, butcher paper, plastic wrap, baking cups, oven bags and slow cooker liners.

Share on Social Networks: